Nascent Biotech INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OTC.Pink
Nascent Biotech aims to raise capital for Phase 2 clinical trials and administrative expenses through a self-underwritten public offering of 20,000,000 shares of common stock at $0.15 per share.
OTC.Pink
Nascent Biotech aims to raise capital for Phase 2 clinical trials and administrative expenses through a stock offering involving the sale and resale of common stock and warrants.
OTC.Pink
Nascent Biotech is seeking to raise capital through a share offering to fund Phase 2 clinical trials for its cancer drug, Pritumumab, and cover general administrative expenses.